{"product_id":"how-estrogen-signaling-helps-cancer-hide-from-the-immune-system-what-patients-need-to-know","title":"How Estrogen Signaling Helps Cancer Hide From the Immune System: What Patients Need to Know","description":"\u003cp\u003eImmune checkpoint blockade (ICB) therapies have revolutionized cancer treatment, yet many patients do not respond or develop resistance, and some experience serious side effects. This commentary highlights a groundbreaking study showing that estrogen receptor α (ERα) signaling in immune cells called macrophages helps tumors suppress the body's natural defenses by disabling CD8+ T cells. Using melanoma models, researchers demonstrated that adding fulvestrant—a drug already approved for breast cancer—significantly enhanced the anti-tumor effects of immunotherapy. These findings provide a strong rationale for clinical trials testing the combination of antiestrogens with immune checkpoint inhibitors in patients with melanoma, triple-negative breast cancer, and potentially other solid tumors.\u003c\/p\u003e\n\n\u003ch1\u003eHow Estrogen Signaling Helps Cancer Hide From the Immune System: What Patients Need to Know\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why Immunotherapy Sometimes Fails\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#estrogen-role\"\u003eThe Estrogen Connection: How ERα Shapes the Tumor Environment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How Researchers Investigated ERα and Melanoma\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: Estrogen Fuels Immune Suppression\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#fulvestrant\"\u003eFulvestrant: Blocking Estrogen to Boost Immunotherapy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#e1-e2\"\u003eEstrone vs. Estradiol: Two Estrogens, Different Effects\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Breast Cancer Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What This Research Cannot Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: What Patients Should Know and Ask\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eEstrogen receptor signaling in macrophages suppresses CD8+ T cells, helping tumors evade immune attack.\u003c\/li\u003e\n\u003cli\u003eIn mouse melanoma models, fulvestrant alone slowed tumor growth; combined with anti-PD-1 it worked even in resistant tumors.\u003c\/li\u003e\n\u003cli\u003eAntiestrogen therapy might help patients whose tumors lack estrogen receptors, because the effect is on immune cells.\u003c\/li\u003e\n\u003cli\u003eFulvestrant plus immunotherapy has not yet been tested in humans; clinical trials are needed to confirm these findings.\u003c\/li\u003e\n\u003cli\u003eObesity raises estrone levels, which may promote inflammation and cancer risk; maintaining a healthy weight is advisable.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why Immunotherapy Sometimes Fails\u003c\/h2\u003e\n\n\u003cp\u003eImmune checkpoint blockade (ICB) therapies are now a standard treatment for many solid tumors. These drugs work by \"releasing the brakes\" on the immune system, allowing the body's own T cells to recognize and attack cancer cells. Drugs such as pembrolizumab (Keytruda), nivolumab (Opdivo), and others have transformed care for cancers including melanoma, lung cancer, kidney cancer, and bladder cancer.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the reality is more complicated. While some patients experience exceptional, long-lasting responses, many others do not benefit at all. Two major problems limit the effectiveness of ICBs: \u003cstrong\u003eintrinsic resistance\u003c\/strong\u003e (the tumor does not respond from the start) and \u003cstrong\u003eacquired resistance\u003c\/strong\u003e (the tumor initially responds but later stops responding). Additionally, ICBs can trigger life-threatening side effects related to over-activation of the immune system, such as severe inflammation of the lungs, colon, or other organs.\u003c\/p\u003e\n\n\u003cp\u003eThis is why researchers are urgently seeking alternative strategies that can \u003cstrong\u003eincrease ICB responses without adding more toxicity\u003c\/strong\u003e. One promising avenue, explored in the study highlighted by this commentary, involves estrogen—a hormone most people associate with reproduction, but which also plays a powerful role in the immune system.\u003c\/p\u003e\n\n\u003ch2 id=\"estrogen-role\"\u003eThe Estrogen Connection: How ERα Shapes the Tumor Environment\u003c\/h2\u003e\n\n\u003cp\u003eOne of the limitations of conventional cancer treatment is that it does not fully account for the interactions between tumor cells and their surrounding environment, known as the \u003cstrong\u003etumor microenvironment (TME)\u003c\/strong\u003e. Most targeted cancer therapies focus on the cancer cells themselves, ignoring the essential \"host\" support cells—including immune cells, blood vessels, and fat cells—that surround the tumor. Healthy host cells are inherently more genetically stable than cancer cells, which means they could provide a less variable target for emerging therapies.\u003c\/p\u003e\n\n\u003cp\u003eEstrogen receptor α (ERα) is a protein found in many different cell types throughout the body. Its activity is involved in multiple aspects of normal human physiology, including the growth and development of female reproductive tissues, bone integrity, cardiovascular and central nervous system functions, normal mammary (breast) development, and the immune response.\u003c\/p\u003e\n\n\u003cp\u003eStudies have long suggested that sex differences in immune responses to cancer may be linked to circulating steroid hormones. A 2018 meta-analysis evaluating randomized trials of ICB agents across multiple cancer types—including melanoma, non-small cell lung cancer, renal cell (kidney) cancer, urothelial (bladder) cancer, head and neck cancer, gastric cancer, and mesothelioma—found that \u003cstrong\u003eoverall survival rates for men were substantially higher than those for women\u003c\/strong\u003e. However, that analysis excluded clinical trials of anti–PD-L1 drugs, and a more recent meta-analysis found that a patient's sex was not associated with ICB efficacy. The debate about true sex differences in immunotherapy response remains unresolved.\u003c\/p\u003e\n\n\u003cp\u003eNevertheless, evidence from patients who did \u003cem\u003enot\u003c\/em\u003e receive ICB therapy suggests that \u003cstrong\u003ehigh estrogen levels and ERα signaling increase the risk of developing melanoma in women\u003c\/strong\u003e. Conversely, women with breast cancer who received adjuvant antiestrogen therapy had a lower risk of developing a second, primary melanoma compared with the general population. The study featured in this commentary (by Chakraborty and colleagues) is especially relevant because \u003cstrong\u003emen also have circulating estrogens\u003c\/strong\u003e, meaning the findings could apply to cancers in both sexes.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How Researchers Investigated ERα and Melanoma\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers began by analyzing \u003cstrong\u003etranscriptomic data sets\u003c\/strong\u003e—genetic information showing which genes are active—from patients with melanoma. Their goal was to test whether there were correlations between specific immune cell \"signatures\" in the tumor and how well patients responded to ICB therapy.\u003c\/p\u003e\n\n\u003cp\u003eThey focused on two types of suppressive myeloid cells commonly found in the tumor microenvironment: \u003cstrong\u003emyeloid-derived suppressor cells (MDSCs)\u003c\/strong\u003e and \u003cstrong\u003etumor-associated macrophages (TAMs)\u003c\/strong\u003e. Macrophages are immune cells that normally help clear infections, but in tumors, they can be \"reprogrammed\" to support cancer growth.\u003c\/p\u003e\n\n\u003cp\u003eThe key findings from this analysis were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMDSC signatures were \u003cstrong\u003enot\u003c\/strong\u003e predictive of a patient's response to ICB therapy.\u003c\/li\u003e\n  \u003cli\u003eA signature for \u003cstrong\u003epolarized TAMs\u003c\/strong\u003e (macrophages that have shifted toward a specific activation state) \u003cem\u003ewas\u003c\/em\u003e associated with response.\u003c\/li\u003e\n  \u003cli\u003eSpecifically, enrichment of the \u003cstrong\u003eM1 macrophage gene signature\u003c\/strong\u003e—but not the M2 signature—was associated with better responses to ICB therapy.\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eM1\/M2 ratio gene signature\u003c\/strong\u003e was associated with better overall survival in patients with melanoma receiving ICB therapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eM1 macrophages are generally considered \"pro-inflammatory\" and help fight tumors, while M2 macrophages are \"anti-inflammatory\" and promote tumor growth. A higher M1\/M2 ratio indicates a tumor environment more favorable to immune attack.\u003c\/p\u003e\n\n\u003cp\u003eBuilding on these observations, the researchers hypothesized that ERα signaling was modulating the tumor microenvironment, leading to ICB resistance. They tested this theory using \u003cstrong\u003emelanoma as a model\u003c\/strong\u003e because melanoma cells themselves express negligible levels of ERα—an important detail. This allowed the researchers to isolate the effects of estrogen signaling on the surrounding immune cells rather than on the cancer cells directly, establishing what scientists call a \u003cstrong\u003ecancer cell–extrinsic\u003c\/strong\u003e mechanism.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: Estrogen Fuels Immune Suppression\u003c\/h2\u003e\n\n\u003cp\u003eThe preclinical studies produced several critical results. First, the researchers used \u003cstrong\u003ethree separate syngeneic murine melanoma models\u003c\/strong\u003e—mouse models in which the immune system is fully intact, allowing study of immune responses. In these models, they treated tumor-bearing mice that had undergone ovariectomy (removal of the ovaries, eliminating natural estrogen) with \u003cstrong\u003e17β-estradiol (E2)\u003c\/strong\u003e, the most potent form of estrogen. E2 treatment led to \u003cstrong\u003eincreased tumor growth\u003c\/strong\u003e in all models.\u003c\/p\u003e\n\n\u003cp\u003eThey also used an \u003cstrong\u003eautochthonous\u003c\/strong\u003e (spontaneously developing) mouse model of melanoma driven by the activated B-Raf\u003csup\u003eV600E\u003c\/sup\u003e mutation and homozygous deletion of the Pten gene. Again, E2 treatment led to increased tumor growth.\u003c\/p\u003e\n\n\u003cp\u003eTo understand \u003cem\u003ehow\u003c\/em\u003e estrogen was promoting tumor growth, the researchers performed \u003cstrong\u003eRNA-Seq\u003c\/strong\u003e (a technique that measures gene expression) on tumor-infiltrating immune cells. They found that E2 treatment caused significant changes in gene expression patterns in tumor-associated macrophages. When they eliminated ERα specifically from myeloid cells in mice, the immunosuppressive effects were reversed.\u003c\/p\u003e\n\n\u003cp\u003eThis led the researchers to a clear conclusion: \u003cstrong\u003eERα signaling increases the immunosuppressive activities of tumor-infiltrating myeloid cells\u003c\/strong\u003e. In plain terms, when estrogen binds to its receptor on macrophages within the tumor, it \"teaches\" those macrophages to suppress the activity of both CD4+ and CD8+ T cells—the very cells the immune system needs to kill cancer. This is a direct effect of estrogen on macrophages that suppresses the proliferation and activity of T cells.\u003c\/p\u003e\n\n\u003ch2 id=\"fulvestrant\"\u003eFulvestrant: Blocking Estrogen to Boost Immunotherapy\u003c\/h2\u003e\n\n\u003cp\u003eHaving established that ERα signaling suppresses the immune response, the researchers asked a logical next question: Could blocking ERα with a drug improve the effectiveness of immunotherapy?\u003c\/p\u003e\n\n\u003cp\u003eThey turned to \u003cstrong\u003efulvestrant\u003c\/strong\u003e (brand name Faslodex), a \u003cstrong\u003eselective estrogen receptor downregulator (SERD)\u003c\/strong\u003e that is already approved for the treatment of breast cancer. Unlike drugs that simply block estrogen from binding (like tamoxifen), SERDs cause the estrogen receptor to be degraded, essentially removing it from the cell.\u003c\/p\u003e\n\n\u003cp\u003eThe results were striking. In all three syngeneic melanoma models, \u003cstrong\u003esubstantial tumor growth inhibition was observed when fulvestrant was given alone\u003c\/strong\u003e, at a dose comparable to that used in patients with breast cancer. This means fulvestrant alone—without any immunotherapy—was able to slow melanoma growth by blocking ERα signaling and relieving immune suppression.\u003c\/p\u003e\n\n\u003cp\u003eEven more promising was the combination approach. The researchers tested \u003cstrong\u003efulvestrant combined with anti–PD-1 immunotherapy\u003c\/strong\u003e (a checkpoint inhibitor targeting the programmed cell death 1 protein) in \u003cstrong\u003eboth PD-1–sensitive and PD-1–resistant\u003c\/strong\u003e melanoma models. In both models, the \u003cstrong\u003ecombination outperformed either single agent alone\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThis is a critical finding. The fact that fulvestrant could restore sensitivity in a PD-1–resistant model suggests that adding antiestrogen therapy might help the roughly 60-70% of patients who do not respond to ICB therapy in the first place, as well as those whose tumors become resistant over time.\u003c\/p\u003e\n\n\u003cp\u003eTaken together, the in vivo (living animal) studies indicate that \u003cstrong\u003epharmacological targeting of ERα can improve the efficacy of immune checkpoint inhibitors\u003c\/strong\u003e—a result with direct implications for human clinical trials.\u003c\/p\u003e\n\n\u003ch2 id=\"e1-e2\"\u003eEstrone vs. Estradiol: Two Estrogens, Different Effects\u003c\/h2\u003e\n\n\u003cp\u003eThe commentary authors also raise an important scientific nuance: \u003cstrong\u003enot all estrogens are the same\u003c\/strong\u003e. A critical issue in evaluating this research involves the choice of which estrogen is being studied. Recent data have shown that \u003cstrong\u003eestrone (E1)\u003c\/strong\u003e—the estrogen that dominates after menopause—is not simply a slightly weaker version of estradiol (E2). Instead, E1 evokes a \u003cstrong\u003ecritically different ERα-regulated transcriptome\u003c\/strong\u003e (pattern of gene activation), with an emphasis on proinflammatory pathways mediated by a signaling molecule called \u003cstrong\u003eNF-κB\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eHere is the relevant biology in simpler terms:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eBefore menopause, the ovaries produce large amounts of \u003cstrong\u003eestradiol (E2)\u003c\/strong\u003e, the most biologically potent estrogen.\u003c\/li\u003e\n  \u003cli\u003eAfter menopause, ovarian E2 production declines dramatically, and \u003cstrong\u003eestrone (E1)\u003c\/strong\u003e becomes the dominant estrogen. E1 is synthesized from adrenal androstenedione by the enzyme \u003cstrong\u003earomatase\u003c\/strong\u003e, primarily in fat tissue.\u003c\/li\u003e\n  \u003cli\u003eIn obesity, androstenedione synthesis remains unchanged, but its conversion (aromatization) to E1 in fat tissue increases.\u003c\/li\u003e\n  \u003cli\u003eConsequently, \u003cstrong\u003ewomen with obesity have two to four times higher E1 levels\u003c\/strong\u003e than women of normal weight.\u003c\/li\u003e\n  \u003cli\u003eBoth obesity and high E1 levels correlate with a greater risk of estrogen-receptor–positive breast cancer after menopause.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAdipocytes (fat cells) play an active role in this process. They mediate inflammation and immunosuppression by activating NF-κB and inducing cytokines (cell-signaling proteins). Adipose tissue releases cytokines that \u003cstrong\u003erecruit macrophages and T cells\u003c\/strong\u003e, inducing chronic inflammation. An expanded pre-adipocyte population produces proinflammatory cytokines, including \u003cstrong\u003eIL-6, IL-8, and CCL2\u003c\/strong\u003e, which drive pre-adipocyte proliferation and stimulate \u003cstrong\u003eIL-1β and TNF-α\u003c\/strong\u003e, perpetuating a cycle of inflammation that supports tumor growth.\u003c\/p\u003e\n\n\u003cp\u003eRecent experiments in breast cancer models indicate that the tumor-promoting activities of E2 are \u003cstrong\u003efar less than those of E1\u003c\/strong\u003e. This may explain the mechanism by which receptor inactivation by SERDs (like fulvestrant) decreases the proinflammatory and immunosuppressive environment within tumors.\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding this distinction opens the possibility of \u003cstrong\u003eblocking estrogen production entirely\u003c\/strong\u003e rather than just blocking its receptor. This could be accomplished using an \u003cstrong\u003earomatase inhibitor (AI)\u003c\/strong\u003e—drugs like letrozole, anastrozole, or exemestane that block the enzyme responsible for converting androgens into estrogens—in postmenopausal women. In premenopausal women, \u003cstrong\u003eovarian suppression therapy\u003c\/strong\u003e (using medications or surgery to stop ovarian estrogen production) could be combined with an aromatase inhibitor for a more complete blockade of both E1 and E2.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Breast Cancer Patients\u003c\/h2\u003e\n\n\u003cp\u003eICB therapy has proven effective for many solid tumors, but its efficacy in treating breast cancer has been modest. This is particularly relevant given the new understanding that ERα has cancer cell–extrinsic effects—meaning estrogen can promote tumor growth not by directly stimulating cancer cells, but by suppressing the immune system's ability to fight those cells.\u003c\/p\u003e\n\n\u003cp\u003eConsider these important facts about breast cancer treatment:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAntiestrogen therapies (like tamoxifen and aromatase inhibitors) are effective for ER-positive breast cancers, but they do \u003cstrong\u003enot\u003c\/strong\u003e work in patients with ER-negative breast cancers, including \u003cstrong\u003etriple-negative breast cancer (TNBC)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eNearly \u003cstrong\u003eone-third of patients with ER-positive disease receive no benefit\u003c\/strong\u003e from antiestrogen therapy.\u003c\/li\u003e\n  \u003cli\u003eAll patients with ER-positive metastatic breast cancer (MBC) ultimately become \u003cstrong\u003erefractory\u003c\/strong\u003e (resistant) to all known antiestrogens.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBecause of these limitations, several clinical studies have explored single-agent ICB therapy in patients with metastatic breast cancer. The results have been sobering but informative:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eIn the \u003cstrong\u003eKEYNOTE-086 study\u003c\/strong\u003e, the response rate to single-agent pembrolizumab in previously treated metastatic triple-negative breast cancer (mTNBC) was only \u003cstrong\u003e5.3%\u003c\/strong\u003e. However, a subset of patients with PD-L1–positive tumors who had \u003cstrong\u003enot\u003c\/strong\u003e received previous treatment had an objective response rate (ORR) of \u003cstrong\u003e21.4%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eIn the \u003cstrong\u003eKEYNOTE-028 study\u003c\/strong\u003e, single-agent pembrolizumab in PD-L1–positive advanced ER-positive breast cancer produced an ORR of \u003cstrong\u003e12.0%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAlthough these overall response rates are modest, \u003cstrong\u003eselect patients do achieve durable responses\u003c\/strong\u003e—meaning their tumors shrink and stay controlled for extended periods. The challenge is identifying those patients and finding ways to turn non-responders into responders.\u003c\/p\u003e\n\n\u003cp\u003eThe commentary authors note that ER-positive breast cancer is thought to be \u003cstrong\u003erelatively immunologically \"cold\"\u003c\/strong\u003e compared with TNBC. This means ER-positive tumors tend to have:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eLower levels of \u003cstrong\u003eCD8+ tumor-infiltrating lymphocytes\u003c\/strong\u003e (killer T cells that have entered the tumor)\u003c\/li\u003e\n  \u003cli\u003eLess \u003cstrong\u003ePD-L1 positivity\u003c\/strong\u003e on both tumor cells and immune cells\u003c\/li\u003e\n  \u003cli\u003eA \u003cstrong\u003elower somatic mutational burden\u003c\/strong\u003e (fewer genetic mutations, which means fewer abnormal proteins for the immune system to recognize as foreign)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTo date, clinical trials testing ICB for breast cancer have been conducted mainly in patients with mTNBC or ER-positive MBC who have already become refractory to antiestrogen therapy. This means the combination of \u003cstrong\u003eICBs with antiestrogens has yet to be tested\u003c\/strong\u003e—and given the new findings, it could prove highly effective in exactly these patient populations.\u003c\/p\u003e\n\n\u003cp\u003ePerhaps most intriguing is the possibility that drugs like fulvestrant could have a role in tumors where the cancer cells themselves are ER-negative, such as TNBC or melanoma. Because estrogen's immunosuppressive effects are mediated through immune cells in the tumor microenvironment—not through the cancer cells—blocking ERα in immune cells could benefit patients regardless of whether their tumors express estrogen receptors.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What This Research Cannot Prove\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to understand that the study highlighted in this commentary is a \u003cstrong\u003epreclinical investigation\u003c\/strong\u003e—the experiments were conducted in mice and with patient data analyzed retrospectively. While the results are compelling, they cannot directly prove that antiestrogens will improve immunotherapy outcomes in humans.\u003c\/p\u003e\n\n\u003cp\u003eThe specific limitations include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnimal models do not perfectly replicate human disease.\u003c\/strong\u003e Murine melanoma models, while valuable, do not capture the full complexity of human tumors, the human immune system, or the effects of years of estrogen exposure.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe transcriptomic analysis was correlational.\u003c\/strong\u003e The association between M1\/M2 macrophage ratios and ICB response does not prove a cause-and-effect relationship.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSex differences in ICB response remain controversial.\u003c\/strong\u003e While earlier data suggested men respond better, more recent meta-analyses have not confirmed this, so the role of estrogen in human ICB responses is not fully settled.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFulvestrant has not yet been tested in combination with ICB in human cancer patients.\u003c\/strong\u003e The promising results in mice need confirmation in clinical trials.\u003c\/li\u003e\n  \u003cli\u003eThe commentary distinguishes between E1 and E2, but most existing clinical data on estrogen and cancer have focused on E2. More research is needed on the specific role of E1 in immunosuppression.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAdditionally, this is a \u003cstrong\u003ecommentary article\u003c\/strong\u003e, not an original research paper. It summarizes and interprets the findings of the study by Chakraborty and colleagues, placing them in a larger scientific context. The viewpoints expressed are the authors' expert interpretations, not direct experimental results.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: What Patients Should Know and Ask\u003c\/h2\u003e\n\n\u003cp\u003eFor patients currently undergoing or considering cancer treatment, this research offers both hope and practical context. While no immediate changes to clinical practice are warranted based on this single study, the findings point toward important future directions:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor patients with breast cancer:\u003c\/strong\u003e If you have metastatic disease and have exhausted standard antiestrogen therapies, ask your oncologist whether clinical trials involving immunotherapy are available. The combination of antiestrogens with ICB has not yet been tested in trials, but this is an area of active interest.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor patients with melanoma:\u003c\/strong\u003e If you have not responded to immune checkpoint inhibitors or have developed resistance, discuss with your oncology team whether any clinical trials are exploring combination approaches, including hormonal agents.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor patients with triple-negative breast cancer:\u003c\/strong\u003e Even though your tumor cells may not express estrogen receptors, the new research suggests estrogen signaling in immune cells could still affect your tumor's ability to evade the immune system. This means antiestrogen therapy might someday be beneficial even for ER-negative disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand the context:\u003c\/strong\u003e A response rate of 5.3% or 12.0% in breast cancer trials sounds low, but it is important to remember that some patients experience \u003cem\u003edurable\u003c\/em\u003e responses—meaning long-term benefit. Researchers are working to identify which patients are most likely to benefit and how to expand that group.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLifestyle considerations:\u003c\/strong\u003e The link between obesity, elevated estrone levels, and increased cancer risk (particularly ER-positive breast cancer after menopause) reinforces the importance of maintaining a healthy weight. This is not medical advice to begin a crash diet during treatment, but it is a factor worth discussing with your care team.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWatch for clinical trials:\u003c\/strong\u003e The commentary explicitly states that these results \"provide a rationale for human trials to test the combination of antiestrogens with ICBs.\" Patients who are interested in emerging treatments should ask their oncologists about clinical trial registries and whether they might be eligible for any upcoming studies.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIt is also worth noting that fulvestrant is already an approved, well-understood drug with a known safety profile. This could accelerate the path to clinical trials, as researchers already understand the drug's dosing, side effects, and interactions, potentially shortening the time needed to bring this combination approach to patients.\u003c\/p\u003e\n\n\u003cp\u003eFinally, patients should understand that science moves step by step. The progression from mouse models to human trials is a necessary path, and while it can feel slow, each step builds the foundation for safer, more effective treatments. The findings highlighted in this commentary represent one such important step.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is immune checkpoint blockade and why does it sometimes fail?\u003c\/h3\u003e\n\u003cp\u003eImmune checkpoint blockade (ICB) uses drugs like pembrolizumab or nivolumab to release the brakes on T cells so they can attack cancer. However, many tumors do not respond at all (intrinsic resistance) or stop responding later (acquired resistance). ICB can also cause severe side effects from over-activation of the immune system, such as lung or colon inflammation.\u003c\/p\u003e\n\u003ch3\u003eHow does estrogen affect the immune system's ability to fight cancer?\u003c\/h3\u003e\n\u003cp\u003eEstrogen binds to receptors on macrophages in the tumor and 'teaches' them to suppress CD4+ and CD8+ T cells, the immune cells needed to kill cancer. This happens through estrogen receptor α (ERα) signaling in these immune cells. Blocking this signaling can relieve that immune suppression and help T cells attack the tumor.\u003c\/p\u003e\n\u003ch3\u003eWhat is fulvestrant and how might it help with immunotherapy?\u003c\/h3\u003e\n\u003cp\u003eFulvestrant is a drug already approved for breast cancer. It degrades estrogen receptors rather than just blocking them. In mouse melanoma models, fulvestrant alone slowed tumor growth. When combined with anti-PD-1 immunotherapy, it worked even in tumors that were resistant to anti-PD-1 alone, suggesting it could boost immunotherapy responses.\u003c\/p\u003e\n\u003ch3\u003eCould antiestrogen therapy help triple-negative breast cancer even though those tumors are ER-negative?\u003c\/h3\u003e\n\u003cp\u003eYes, possibly. This research shows estrogen can promote tumor growth by acting on immune cells in the tumor environment, not directly on cancer cells. So even if a tumor lacks estrogen receptors, blocking estrogen signaling in immune cells might help the immune system fight the cancer. This has not yet been proven in humans.\u003c\/p\u003e\n\u003ch3\u003eWhat should melanoma patients who haven't responded to immunotherapy know from this research?\u003c\/h3\u003e\n\u003cp\u003eIn mouse models, adding fulvestrant restored sensitivity to anti-PD-1 in resistant melanoma tumors. This suggests that combining antiestrogen drugs with immunotherapy might help some patients who do not respond initially or who become resistant. However, this combination has not been tested in human trials, so patients should ask their oncologist about clinical trial options.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of this research on estrogen and immunotherapy?\u003c\/h3\u003e\n\u003cp\u003eThis was a preclinical study in mice, not humans. Mouse models do not fully capture human disease. The gene signature analysis was correlational, not proof of cause and effect. Also, sex differences in immunotherapy response remain controversial. Fulvestrant plus immunotherapy has not been tested in human patients, so clinical trials are needed to confirm these findings.\u003c\/p\u003e\n\u003ch3\u003eAre there clinical trials combining antiestrogens with immunotherapy?\u003c\/h3\u003e\n\u003cp\u003eThe article states that clinical trials testing antiestrogens combined with immune checkpoint inhibitors have not yet been conducted. However, the findings provide a strong rationale for such trials. Since fulvestrant is already an approved drug with a known safety profile, researchers may be able to design trials more quickly. Patients interested in emerging treatments should ask their oncologist about trial registries.\u003c\/p\u003e\n\u003ch3\u003eShould I seek a second opinion about adding antiestrogen therapy to my immunotherapy for melanoma or breast cancer?\u003c\/h3\u003e\n\u003cp\u003eA second opinion can be valuable if you have melanoma or breast cancer and are considering whether antiestrogen therapy might improve your response to immunotherapy. Research in mouse models shows that blocking estrogen receptor signaling with fulvestrant can slow tumor growth and enhance anti-PD-1 immunotherapy, even in resistant tumors. However, this combination has not yet been tested in human trials, so no standard recommendation exists. A second opinion can help you understand whether you might be eligible for clinical trials exploring this approach and review your tumor's immune environment. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e role of estrogen receptor signaling in suppressing the immune response to cancer\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e James M. Rae and Marc E. Lippman\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e The Journal of Clinical Investigation (J Clin Invest), 2021;131(24):e155476. Published December 15, 2021. https:\/\/doi.org\/10.1172\/JCI155476\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eType:\u003c\/strong\u003e Commentary article\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e Dr. Rae is affiliated with the Division of Hematology and Oncology, Department of Internal Medicine, and the Department of Pharmacology at the University of Michigan Medical School, Ann Arbor, Michigan. Dr. Lippman is affiliated with the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRelated original research:\u003c\/strong\u003e The commentary discusses the study by Chakraborty et al., \"Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma,\" published in the Journal of Clinical Investigation, 2021;131(23):e151347. https:\/\/doi.org\/10.1172\/JCI151347\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of interest disclosure:\u003c\/strong\u003e Dr. Lippman has equity in and receives income from Seattle Genetics Inc.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and is not a substitute for professional medical advice. Patients should discuss all treatment decisions with their oncology care team.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47471115337884,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/it\/products\/how-estrogen-signaling-helps-cancer-hide-from-the-immune-system-what-patients-need-to-know","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}